Dr. Bernard A. Fox is a Founder, President, and CEO of UbiVac, a clinical-stage immuno-oncology company developing first-in-class cancer vaccines that target previously untapped regions of the cancer genome. A nationally recognized leader in tumor immunology, Dr. Fox brings decades of experience advancing immune-based therapies from the lab to the clinic. Dr. Fox trained under immunotherapy pioneer Dr. Steven A. Rosenberg at the National Cancer Institute, where he helped lay the foundation for modern T-cell therapies. Building on that foundation, he launched UbiVac to develop innovative immunotherapies that address critical unmet needs in oncology. Under his leadership, UbiVac has developed DPV-001, a groundbreaking off-the-shelf cancer vaccine that concentrates non-canonical “Dark Matter” proteins—novel antigens derived from cancer’s dark genome. In early trials, combination immunotherapy including DPV-001 has tripled response rates compared to anti-PD-1 therapy alone, with promising signs of broader immune activation applicable to essentially all solid cancers. Dr. Fox has forged strategic collaborations with pharmaceutical partners, and academic centers, to accelerate UbiVac’s path to market. He holds multiple patents, has authored over 200 publications, and serves in leadership roles across national and international cancer research networks. With a strong scientific foundation, validated clinical data, and a differentiated therapeutic approach, Dr. Fox is positioning UbiVac to lead a new era of immunotherapy and deliver outsized value to patients and investors alike.